Tenacia Biotechnology
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $120M
Overview
Clinical-stage biotech developing small molecule therapies for oncology and immunology using proprietary drug discovery platforms.
OncologyImmunology
Technology Platform
Proprietary structure-based drug design and fragment-based screening platforms for small molecule discovery against challenging targets in oncology and immunology.
Opportunities
Growing Chinese biopharma market with supportive regulatory reforms, unmet needs in targeted oncology therapies, and potential for strategic partnerships with global pharmaceutical companies.
Risk Factors
Intense competition in oncology/immunology space, regulatory challenges for clinical development and approval, dependence on continued funding in volatile capital markets.
Competitive Landscape
Competes with both multinational pharma and domestic Chinese biotechs in targeted therapy space; differentiation through proprietary discovery platforms and focus on specific resistance mechanisms in cancer.